← 返回前沿论文

NKG2D 配体的表观遗传调控与 NK 细胞免疫治疗在肿瘤治疗中的兴起

英文原题:Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment.

PubMed 2024/08/05(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

研究概要

表观遗传修饰影响基因表达,并影响癌症的发生和进展。

中文摘要

表观遗传修饰影响基因表达,并影响癌症的发生和进展。因此,它们可作为诊断和预后生物标志物以及潜在的治疗靶点。自然杀伤(NK)细胞是先天免疫系统的重要组成部分,通过激活性和抑制性配体的平衡来识别和清除癌细胞,从而发挥抗肿瘤作用。理解NK细胞配体的表观遗传调控为增强NK细胞介导的肿瘤清除提供了见解。本综述探讨了调控激活性NKG2D配体表达的表观遗传修饰,并讨论了研究基于NK细胞免疫疗法的临床试验,强调其作为有效癌症治疗策略的潜力。在不同癌症类型(如急性髓系白血病(AML)和非小细胞肺癌(NSCLC))中检验NK细胞疗法安全性和有效性的案例研究显示,其结果令人鼓舞且毒性极小。这些发现强调了NKG2D配体的表观遗传调控和基于NK细胞的免疫疗法作为有效癌症治疗策略的治疗前景。未来在推进个性化医学方法以及与NK细胞联合的新组合疗法方面的研究将进一步改善治疗结果,并为治疗各种类型癌症患者提供新的治疗选择。

展开英文摘要原文

Epigenetic modifications influence gene expression and effects cancer initiation and progression. Therefore, they serve as diagnostic and prognostic biomarkers and potential therapeutic targets. Natural Killer (NK) cells, integral to the innate immune system, exhibit anti-tumor effect by recognizing and eliminating cancerous cells through the balance of activating and inhibitory ligands. Understanding the epigenetic regulation of NK cell ligands offers insights into enhancing NK cell-mediated tumor eradication. This review explores the epigenetic modifications governing the expression of activating NKG2D ligands and discusses clinical trials investigating NK cell-based immunotherapies, highlighting their potential as effective cancer treatment strategies. Case studies examining the safety and effectiveness of NK cell therapies in different cancer types, such as acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC), demonstrate promising outcomes with minimal toxicity. These findings underscore the therapeutic prospects of epigenetic modulation of NKG2D ligands and NK cell-based immunotherapies as effective cancer treatment strategies. Future research in the advancement of personalized medicine approaches and novel combination therapies with NK cell will further improve treatment outcomes and provide new therapeutic options for treating patients with various types of cancer.

论文信息

作者
Kumar R、Gupta R
单位
Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, United States.United Kingdom
文献类型
综述
期刊
Frontiers in oncology2024
原文标识
PubMed 39161385 · DOI 10.3389/fonc.2024.1456631